

# Drug Policy

|                |                           |   |
|----------------|---------------------------|---|
| <b>Policy:</b> | <b>Eliquis (apixaban)</b> | <b>Annual Review Date:</b><br><b>03/16/2023</b><br><br><b>Last Revised Date:</b><br><b>03/16/2023</b> |
|----------------|---------------------------|---|

## OVERVIEW

Eliquis are oral factor Xa inhibitor anticoagulants indicated for reduction in the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery, for treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.

## POLICY STATEMENT

This policy involves the use of Eliquis. Prior authorization is recommended for pharmacy benefit coverage of Eliquis. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below.

**Automation:** When available, the following ICD-10 codes and corresponding approval durations will be used for automation to allow approval of the requested medication:

1. I48.\*; I82.\*; I27.82; 1 year
2. Z96.6\*; 60 days

## RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Eliquis is recommended in those who meet the following criteria:

1. **Atrial Fibrillation, Nonvalvular (or Atrial Flutter)**  
**Criteria.** *Approve for 1 year.*
2. **Deep Vein Thrombosis (DVT) in Patients Undergoing Hip or Knee Replacement Surgery, Prophylaxis**  
**Criteria.** *Approve for 60 days.*

# Drug Policy

### 3. Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), Treatment

**Criteria.** Approve for 1 year.

### 4. Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) to Reduce the Risk of Recurrence

**Criteria.** Approve for 1 year.

#### **Initial Approval/ Extended Approval.**

indication specific, see above.

---

#### **OTHER USES WITH SUPPORTIVE EVIDENCE**

### 5. Treatment or Prevention of Other Thromboembolic-Related Conditions (e.g., superficial vein thrombosis, splanchnic vein thrombosis, hepatic vein thrombosis, prophylaxis of venous thromboembolism [VTE] in high-risk patients)

**Criteria.** Approve for 6 months if the patient meets ONE of the following criteria (A, B, or C):

- A. The patient has tried warfarin, fondaparinux injection, or a low molecular weight heparin (LMWH) product (e.g., enoxaparin injection, Fragmin [dalteparin injection]); OR
- B. The patient has tried another direct oral anticoagulant (e.g. Pradaxa, Savaysa, Xarelto); OR
- C. The patient has been started on Eliquis for the treatment of an acute thromboembolic condition.

#### **Initial Approval/ Extended Approval.**

indication specific, see above.

---

#### **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Eliquis have not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. **Venous Thromboembolism in an Acutely Ill Medical Patient, Prophylaxis.** (Note: This includes post-discharge thromboprophylaxis for a patient hospitalized with coronavirus disease 19 [COVID-19]). Eliquis has been compared with enoxaparin for post-discharge prophylaxis in acutely ill medical patients; however, superiority vs. enoxaparin was not achieved, and bleeding was increased with Eliquis.<sup>10</sup> Xarelto and Bevyxxa are labeled for prophylaxis of venous thromboembolism in acutely ill medical patients and are supported in clinical practice guidelines, including guidelines which address prophylaxis of venous thromboembolism in COVID-19 patients.<sup>7-9</sup>
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

#### **Documentation Requirements:**

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation

---

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

# Drug Policy

supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

## REFERENCES

1. Eliquis® tablets [prescribing information]. Princeton, NJ and New York, NY: Bristol-Myers Squibb and Pfizer; November 2019.
2. Guyatt GH, Akl EA, Crowther M, et al, for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141:7S-47S.
3. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. *Chest*. 2016;149(2):315-352.
4. The NCCN Cancer-Associated Venous Thromboembolic Disease Clinical Practice Guidelines in Oncology (Version 1.2020—April 16, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on November 2, 2020.
5. Lip G, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. *Chest*. 2018;154(5):1121-1201.
6. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2019;74(1):104-132.
7. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. *Chest*. 2020 Sep;158(3):1143-1163.
8. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*. 2020; 18: 1859– 1865.
9. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. *J Thromb Thrombolysis*. 2020 Jul;50(1):72-81.
10. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *N Engl J Med*. 2011 Dec 8;365(23):2167-77.